Cargando…
MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway
Background: Acute myeloid leukemia (AML) is a group of heterogeneous hematologic malignancies correlates with poor prognosis. It is important to identify biomarkers for effective treatment of AML. Kinases participate in many regulatory pathways and biological activities in AML. Previous studies demo...
Autores principales: | Ling, Qing, Li, Fenglin, Zhang, Xiang, Mao, Shihui, Lin, Xiangjie, Pan, Jiajia, Ye, Wenle, Wei, Wenwen, Qian, Yu, Hu, Chao, Huang, Xin, Wang, Jinghan, Wang, Huafeng, Huang, Jiansong, Wang, Yungui, Jin, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239467/ https://www.ncbi.nlm.nih.gov/pubmed/34166980 http://dx.doi.org/10.1016/j.ebiom.2021.103441 |
Ejemplares similares
-
Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
por: Mao, Shihui, et al.
Publicado: (2021) -
Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study
por: Lin, Xiangjie, et al.
Publicado: (2021) -
Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia
por: Wang, Jinghan, et al.
Publicado: (2021) -
Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022) -
ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3
‐ITD
por: Qian, Yu, et al.
Publicado: (2023)